







# YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer

Masaya Yamazaki<sup>1,\*</sup> , Shinjiro Hino<sup>2</sup> , Shingo Usuki<sup>3</sup> , Yoshihiro Miyazaki<sup>4</sup>, Tatsuya Oda<sup>4</sup>, Mitsuyoshi Nakao<sup>2</sup> , Takaaki Ito<sup>5</sup>  & Kazuya Yamagata<sup>1</sup> 

## Abstract

Tumor-initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial-mesenchymal transition (EMT)-like signature marked by high expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c-Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor-initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability.

**Keywords** AURKB; BRD4; pancreatic adenocarcinoma; ROR1; tumor-initiating cells

**Subject Category** Cancer

**DOI** 10.15252/emboj.2022112614 | Received 15 September 2022 | Revised 23 March 2023 | Accepted 29 March 2023 | Published online 25 April 2023

**The EMBO Journal (2023) 42: e112614**

See also: [I Peñuelas-Haro & E Espinet](#) (July 2023)

## Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a malignant neoplasm with a poor prognosis. PDAC is highly aggressive, with a propensity for both local invasion and distant metastasis in the early stage, and

is resistant to most treatments (Kleeff *et al*, 2016; Mizrahi *et al*, 2020), resulting in a 5-year overall survival rate of approximately 10% (National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. <https://seer.cancer.gov/statfacts/html/pancreas.html>).

Deep whole-exome sequencing identified a high frequency of somatic DNA mutations in *KRAS* (> 90%), *TP53* (> 70%), *CDKN2A*, and *SMAD4* (both at approximately 30%; Raphael *et al*, 2017). Moreover, 60% of the tumors with wild-type *KRAS* harbored an alternative RAS-MAPK activating pathway, which highlights the importance of the RAS pathway in PDAC. Recently, inhibitors against mutant *KRAS*<sup>G12D</sup> or *KRAS*<sup>G12C</sup> have been developed and have provided hope for breakthrough therapies in malignancies with *KRAS* mutations, including PDAC (Canon *et al*, 2019; Mao *et al*, 2022; Wang *et al*, 2022). However, resistance mechanisms have become uncovered, and thus, other therapeutic strategies have also been explored (Xue *et al*, 2020; Awad *et al*, 2021).

Intratumor heterogeneity contributes substantially to the characteristics of aggressive tumors, such as a high frequency of metastasis and resistance to treatment (Shibue & Weinberg, 2017). In particular, tumor-initiating cells (also referred to as cancer stem cells: CSCs) have been considered the source of cellular heterogeneity (Clarke *et al*, 2006; Shackleton *et al*, 2009; Magee *et al*, 2012). Their highly plastic nature allows tumor-initiating cells to generate a cellular hierarchy similar to that of normal tissue (Marusyk *et al*, 2020). The existence and importance of tumor-initiating cells are evidenced by their capabilities for tumorigenesis, metastasis, and recurrence in multiple malignancies (Bonnet & Dick, 1997; Al-Hajj *et al*, 2003; Singh *et al*, 2003; Dalerba *et al*, 2007; O'Brien *et al*, 2007; Ricci-Vitiani *et al*, 2007; Barker *et al*, 2009; Battle & Clevers, 2017; De Sousa *et al*, 2017; Shimokawa *et al*, 2017). Thus, tumor-initiating cells play a central role in tumor progression. In PDAC, previous studies of intratumor heterogeneity have shown that subpopulations of cells marked by CD44<sup>+</sup>/CD24<sup>+</sup>/ESA<sup>+</sup> (Li *et al*, 2007), CD133 (Hermann *et al*, 2007), DCLK1 (Bailey *et al*, 2014), and Musashi (Fox *et al*, 2016; Lytle *et al*, 2019) are functionally distinct tumor-initiating

1 Department of Medical Biochemistry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

2 Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan

3 Liaison Laboratory Research Promotion Center, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan

4 Department of Gastrointestinal and Hepatobiliary Pancreatic Surgery, University of Tsukuba, Tsukuba, Japan

5 Department of Medical Technology, Faculty of Health Science, Kumamoto Health Science University, Kumamoto, Japan

\*Corresponding author. Tel: +81 96 373 5070; Fax: +81 96 364 6940; E-mail: myamazaki@kumamoto-u.ac.jp

cells. However, at single-cell resolution, it is poorly understood how intratumor heterogeneity is involved in disease progression. In addition, the therapeutic benefit of eradicating tumor-initiating cells in PDAC remains unclear. Here, we conducted single-cell RNA sequencing and functional approaches using human PDAC xenografts to identify targetable tumor-initiating cells. We found that a partial epithelial-mesenchymal transition (EMT)-like subpopulation with high expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) serves as a source of intratumor heterogeneity. We demonstrated that ROR1<sup>high</sup> cells have high tumorigenicity and that ROR1 is functionally crucial for tumor growth, relapse, and metastasis. Moreover, ROR1 activates the E2F transcriptional network through c-Myc, which accelerates tumor proliferation by inducing Aurora kinase B (AURKB). Epigenomic analyses identified the enhancer that supports high expression of *ROR1* through the YAP/BRD4 axis. In addition, a BET inhibitor downregulated *ROR1* and suppressed the proliferation of PDAC organoids. Our current findings indicate that intratumor ROR1<sup>high</sup> cells are tumor-initiating cells in PDAC, emphasizing the potential of strategies targeting ROR1 in PDAC therapy.

## Results

### Single-cell RNA sequencing reveals intratumor heterogeneity in a pancreatic cancer xenograft

To identify cellular diversity in PDAC, we first performed single-cell RNA sequencing (scRNA-seq) in a subcutaneous xenograft generated from the S2-VP10 PDAC cell line using the 10× Genomics platform (Fig 1A and Appendix Fig S1). A total of 993 human PDAC cells were carried forward for downstream analysis after filtering low-quality and mitochondria-enriched cells from 2,655 cells (see Materials and Methods for details). We then performed clustering analysis and visualized the results using uniform manifold approximation and projection (UMAP) implemented in the Seurat package (Stuart *et al*, 2019). This analysis identified six major clusters with distinct gene expression profiles (Figs 1B–E, and EV1A and B): cluster 1 (cycling\_G1 cells, 27.1%); cluster 2 (cycling\_S cells, 17.0%); cluster 3 (cycling\_G2M cells, 7.0%); cluster 4 (slow cycling cells, 26.7%); cluster 5 (autophagy cells, 8.6%); and cluster 6 (partial EMT cells, 13.6%). Cluster 4 exhibited higher expression levels of HIF-1-regulated genes such as *NDRG1* and *VEGFA* (Ellen *et al*, 2008; Fig EV1B), suggesting that these cells were located in hypoxic areas away from blood vessels in the tumor. In cluster 6, EMT-related markers (*ZEB1*, *MSRB3*, and *VIM*) were highly expressed, while the expression of epithelial cell adhesion markers (*CDH1*, *EPCAM*, and *OCN*) was reduced (Fig 1F). However, classical EMT-activating transcription factors (EMT-TFs), such as *ZEB2*, *SNAI1*, *SNAI2*, and *TWIST1*, were barely detectable (Fig EV1C). In addition, this cluster retained the expression of epithelial origin markers, such as *KRT8* and *KRT18* (Dominguez *et al*, 2020; Fig EV1B). Puram *et al* (2017) defined partial EMT as a status characterized by the expression of EMT-associated extracellular matrix genes without classical EMT-TFs in head and neck cancer. Furthermore, Dongre & Weinberg (2019) recently re-defined the partial EMT state as a hybrid of epithelial and mesenchymal phenotypes. In our study, the transcriptional profile of cluster 6 cells closely resembled that of a previously reported partial EMT malignancy.

To estimate the cell lineages and potential cells of origin in the heterogeneous xenograft, we next performed RNA velocity analysis using *velocyto* (La Manno *et al*, 2018), a tool for predicting the future state of individual cells based on a balance between unspliced and spliced mRNAs. We found two distinct velocity flows originating from the partial EMT cluster: (i) to the cycling state, including cycling G1, cycling S, and cycling G2M, and (ii) to the slow-cycling state (Fig 1G). These data suggest that the partial EMT population serves as the source of heterogeneous subpopulations in the xenograft and thus contains tumor-initiating cells.

To investigate the relevance of our findings in the S2-VP10 xenograft to patient PDAC, we analyzed publicly available scRNA-seq data (Peng *et al*, 2019). This analysis revealed two *KRT8/KRT18* populations (Figs 1H and EV2A), and one of the clusters was a tumor cell population expressing malignant markers such as *FXRD3* and *MUC1* (Fig 1I; Peng *et al*, 2019). Based on gene expression characteristics, we identified six distinct cell clusters in malignant cells (Figs 1J, and EV2B and C). In cluster 1, proliferation-related genes such as *MKI67* and *TOP2A* were highly expressed (Fig 1K), suggesting that this population may be a potential origin of tumor growth. In addition, this cluster exhibited higher expression of *VIM* (Fig 1L) but lacked expression of EMT-TFs (Fig EV2D). These data indicate that similar cells with a partial EMT signature exist not only in our xenograft model but also in patient PDAC.

### ROR1 marks the partial EMT population

To isolate potential tumor-initiating cells and validate their properties, we investigated the specific cell surface markers of partial EMT cells. We focused on receptor tyrosine kinases (RTKs) because the aberrant activation of RTKs plays a critical role in the development and progression of cancer (Lemmon & Schlessinger, 2010). From 56 RTK genes, seven candidate genes were selected with the most enriched expression in the partial EMT cluster compared to other clusters: *EPHA4*, *EPHA7*, *ERBB4*, *FGFR1*, *JAK3*, *LYN*, and *ROR1* (Figs 2A, and EV3A and B, and Table EV1). ROR1 is reported as an oncofetal antigen and is widely expressed in multiple human cancers (Zhang *et al*, 2012b). In addition, high expression of *ROR1* is associated with shorter metastasis-free survival in breast cancer (Cui *et al*, 2013). In addition, we found that *ROR1* is highly expressed in the partial EMT subpopulation of patient PDAC as well as S2-VP10 xenografts (Fig 2B and C). Therefore, we focused on ROR1 as a marker for isolating partial EMT cells.

To confirm whether ROR1 is a reliable marker of the partial EMT population, we isolated ROR1<sup>high</sup> and ROR1<sup>low</sup> cells by FACS from xenografts derived from S2-VP10 cells or patient-derived organoid (PDO) #1, and then performed RNA sequencing (Fig 2D–F, and Table EV2 and Dataset EV1). Gene set enrichment analysis (GSEA; Subramanian *et al*, 2005) revealed that intratumor ROR1<sup>high</sup> cells showed upregulation of EMT pathway genes compared with ROR1<sup>low</sup> cells (Fig 2G–J, and Tables EV3 and EV4), consistent with the scRNA-seq data. ROR1<sup>high</sup> cells had higher expression of EMT-related genes but lower expression of epithelial markers than ROR1<sup>low</sup> cells (Fig 2K and L). The partial EMT marker *TGFBI* (Puram *et al*, 2017) was also highly expressed in ROR1<sup>high</sup> cells (Fig 2K and L). ROR1<sup>high</sup> cells showed no significant upregulation of classical EMT TFs, such as *ZEB2*, *SNAI1/2*, and *TWIST1/2*, compared with ROR1<sup>low</sup> cells (Fig EV3C). These results confirmed that ROR1 serves




Figure 1.

**Figure 1. Single-cell transcriptomic analysis in pancreatic tumor xenografts and patient PDAC.**

- A Schematic workflow for single-cell RNA sequencing analysis using the S2-VP10 pancreatic tumor xenograft
- B UMAP plot of scRNA-seq data in the S2-VP10 xenograft. Six clusters of cell populations are indicated by different colors.
- C Heatmap showing the expression of cluster-specific genes. Representative marker genes for each cluster are indicated.
- D Relative proportions of each cluster.
- E Dot plot showing the expression levels and frequencies of marker genes in six subpopulations. The solid (high expression) and dotted (low expression) lines indicate representative markers for each cluster.
- F UMAP plot showing the expression levels of EMT markers. The magenta dotted lines indicate cluster 6 (partial EMT).
- G RNA velocity field projected onto the UMAP plot.
- H UMAP plot of the patient PDAC scRNA-seq data. Normal ductal cells and malignant cells are intermingled.
- I UMAP plots showing the expression levels of normal ductal cell markers (*FXYD2* and *AMBIP*) or malignant cell markers (*FXYD3* and *MUC1*).
- J UMAP plot of malignant cells in the patient PDAC. Different colors represent six clusters of cell populations.
- K Heatmap visualizing the expression levels of proliferation markers.
- L Heatmap showing the expression level of *VIM*.

as a marker for partial EMT cells. Known CSC markers, such as *CD44*, *PROM1* (encoding CD133), and *DCLK1*, did not show a distinctive expression pattern in our scRNA-seq data (Fig EV3D).

### ROR1<sup>high</sup> cells exhibit a high tumor-initiating capacity

We investigated the distribution of ROR1<sup>high</sup> cells in PDAC tissue. Immunohistochemical staining showed heterogeneous expression of ROR1 in patient samples and patient-derived xenografts (PDXs; Fig EV4A and B). Similarly, ROR1<sup>high</sup> cells were heterogeneously present in S2-VP10 and S2-013 xenografts (Fig EV4C). Part of the tumor tissue showed a micropapillary pattern, a factor indicating a poor prognosis (Reid *et al*, 2011), and was positive for ROR1 and pan-cytokeratin (an epithelial malignancy marker) staining (Fig EV4D).

In PDAC patients, high expression of *ROR1* was significantly associated with poor clinical outcomes (disease-specific survival) in the TCGA-PAAD dataset from The Cancer Genome Atlas (TCGA; Fig 3A and Dataset EV2), suggesting a potential role of ROR1 in PDAC progression. To investigate the tumorigenic capacity of ROR1<sup>high</sup> cells, we sorted single cells from xenografts based on their ROR1 expression and examined them in two assays (Fig 3B and Appendix Fig S2). (i) In Matrigel-based cultures *in vitro*, ROR1<sup>high</sup> cells efficiently formed organoids or colonies compared with ROR1<sup>low</sup> cells (Figs 3C and EV5A). In addition, stable *ROR1*-knockdown using a doxycycline (Dox)-inducible shRNA system suppressed S2-VP10 organoid formation (Fig EV5B–D). (ii) An *in vivo* tumor-initiating assay showed that ROR1<sup>high</sup> cells from the PDO#1 xenograft generated tumors with a higher incidence (6/6) than ROR1<sup>low</sup> cells (2/6) when 500 cells were subcutaneously transplanted into *Rag2*<sup>-/-</sup>/*Jak3*<sup>-/-</sup> (BRJ) immunodeficient mice (Fig 3D and E). Similarly, ROR1<sup>high</sup> cells from the S2-VP10 xenograft exhibited higher tumorigenicity than ROR1<sup>low</sup> cells (Fig 3F). In addition, the xenograft derived from ROR1<sup>high</sup> cells in the PDO#1 xenograft histologically recapitulated the original xenografts in terms of hierarchical morphology and cellular differentiation, such as mucus-secreting cells (Fig 3G). Thus, these data demonstrated that intratumor ROR1<sup>high</sup> cells have a greater ability to initiate tumors than ROR1<sup>low</sup> cells and produce differentiated progeny. Although present at a low frequency, ROR1<sup>low</sup> cells also formed tumors with a hierarchical histology similar to the original tumor containing ROR1<sup>high</sup> cells (Fig 3D, F, and G). These results suggest that ROR1<sup>low</sup> cells may revert to ROR1<sup>high</sup> status, contributing to tumor formation.

Since CD44 is reported as a marker of tumor-initiating cells in PDAC (Li *et al*, 2007), we then investigated the relationship between ROR1 and CD44. We observed that both ROR1<sup>high</sup> and ROR1<sup>low</sup> cells express CD44 in scRNA-seq data of S2-VP10 xenograft (Fig EV3D); however, FACS analysis revealed that some of the CD44v9<sup>high</sup> cells coexpressed ROR1 (Fig EV5E). Only this ROR1<sup>high</sup>/CD44v9<sup>high</sup> population exhibited colony-forming capability (Fig EV5F). These data indicate that high ROR1 expression clearly marks tumor-initiating cells.

### ROR1 and its downstream target, AURKB, are essential for tumor growth

To investigate whether ROR1 is functionally involved in tumor growth, we generated xenografts using mCherry-labeled S2-VP10 cells expressing a Dox-inducible shRNA against *ROR1* (S2-VP10-mCherry-*ishROR1*; Fig 4A). *ROR1*-knockdown was maintained *in vivo* by adding doxycycline to the drinking water (Fig 4B). *ROR1*-knockdown (KD) dramatically suppressed tumor growth in mice (Fig 4C–E), suggesting that ROR1 is not only a marker for tumor-initiating cells but also a functional player in PDAC development.

To explore downstream effectors of ROR1 activity, we next performed an integrative analysis of three transcriptomic datasets: (i) PANC-1 cells (ROR1-expressing pancreatic adenocarcinoma cell line) transfected with control versus ROR1 siRNA, (ii) ROR1<sup>high</sup> cells versus ROR1<sup>low</sup> cells in S2-VP10 xenografts, and (iii) ROR1<sup>high</sup> cells versus ROR1<sup>low</sup> cells in PDO#1 xenografts (Fig 4F). This analysis revealed that the E2F transcriptional network is commonly activated in ROR1-enriched samples, such as control-KD and ROR1<sup>high</sup> cells, but is suppressed in *ROR1*-KD and ROR1<sup>low</sup> cells (Fig 4F and Tables EV3–EV5). We identified four E2F target genes (*AURKB*, *CDCA8*, *CDK1*, and *E2F8*) commonly upregulated in the three ROR1-enriched datasets (Fig 4G and H). Aurora kinase B (*AURKB*) plays an important role in mitotic chromosome condensation (Lens *et al*, 2010) and has attracted considerable interest as a potential therapeutic target because of its overexpression in several cancer tissues, such as non-small cell lung carcinoma, glioblastoma, and ovarian cancer (Vischioni *et al*, 2006; Zeng *et al*, 2007; Chen *et al*, 2009). We also confirmed the reduction in *AURKB* protein in ROR1-downregulated S2-VP10 and S2-013 cells (Fig 4I). We next examined whether the kinase activity of *AURKB* is required for PDAC growth using PDO#1 and S2-VP10 organoids. Both tozasertib (a pan-Aurora kinase inhibitor) and barasertib (an Aurora kinase B




Figure 2.

**Figure 2. ROR1 is a surface marker for partial EMT cells in PDAC.**

- A Strategy to identify surface markers for partial EMT cells in the S2-VP10 xenograft.  
 B, C Heatmap visualizing the expression of *ROR1* in the S2-VP10 xenograft (B) and patient PDAC (C).  
 D Outline of the experimental strategy for transcriptome analysis of cells isolated from the S2-VP10 xenograft and PDO#1 xenograft ( $n = 3$ ).  
 E, F Heatmap of DEGs in *ROR1*<sup>high</sup> and *ROR1*<sup>low</sup> cells in the S2-VP10 xenograft (E) or PDO#1 xenograft (F).  
 G, H Gene Set Enrichment Analysis (GSEA) comparing *ROR1*<sup>high</sup> with *ROR1*<sup>low</sup> cells (FDR < 0.25) in the S2-VP10 xenograft (G) or PDO#1 xenograft (H). NES, normalized enrichment score. See also Tables EV3 and EV4.  
 I, J GSEA plot showing significant upregulation of the EMT-related gene set in *ROR1*<sup>high</sup> cells in the S2-VP10 xenograft (I) or PDO#1 xenograft (J).  
 K, L Heatmap showing epithelial, EMT, and partial EMT marker genes that are differentially expressed in *ROR1*<sup>high</sup> versus *ROR1*<sup>low</sup> cells in S2-VP10 xenografts (K) or PDO#1 xenografts (L).

selective inhibitor) markedly suppressed the formation and growth of organoids (Fig 4J). To clarify the importance of AURKB as a downstream effector of ROR1, we examined it in two assays. Stable AURKB expression increased the organoid formation ability of (i) *ROR1*<sup>low</sup> cells derived from S2-VP10 AURKB-EGFP xenografts (Figs 4K, and EV6A and B) and (ii) Dox-inducible *ROR1*-KD cells (Fig EV6A–E). These results indicate that AURKB is a critical downstream target of ROR1 in promoting PDAC cell proliferation.

We then sought to link ROR1 activity to E2F-mediated AURKB expression. Previous reports have shown that ROR1 induces AKT phosphorylation in breast and non-small cell lung cancers (Yamaguchi *et al*, 2012; Zhang *et al*, 2012a). Indeed, we observed a reduction in phospho-AKT levels in *ROR1*-depleted PDAC cells (Fig 4L). Consistent with the reduced AKT signaling, c-Myc protein levels and the expression of c-Myc target genes, such as *CDK4*, *CCND1*, *CDK2*, and *CCNE1*, were downregulated by *ROR1*-KD (Fig 4M and N). In addition, RB phosphorylation levels were also reduced by *ROR1*-KD (Fig 4N), suggesting that RB-mediated inhibition of E2F had been promoted. Taken together, these results indicate that the ROR1 enhances AKT/c-Myc signaling, which in turn promotes the E2F-mediated expression of AURKB (Fig 4O).

**ROR1 depletion prevents relapse after chemotherapy**

Tumor-initiating cells survive cytotoxic exposure through reversible mechanisms, leading to relapse (Boumahdi & de Sauvage, 2020). We investigated the responses of *ROR1*<sup>high</sup> cells to drug treatment in our *in vivo* experimental model. In both the PDO#1 xenograft and S2-VP10 xenograft, gemcitabine treatment led to an increase in *ROR1*<sup>high</sup> cells (Fig 5A and B), suggesting the functional involvement of *ROR1*<sup>high</sup> cells in relapse after chemotherapy. To test this possibility, we evaluated the effect of *ROR1*-KD on tumor relapse using S2-VP10-mCherry-ishROR1 cells. After the administration of gemcitabine, tumor growth temporarily paused but resumed approximately 2 weeks after therapy (Fig 5C, green). In contrast, the combination of *ROR1*-KD (with Dox) and gemcitabine treatment significantly prevented relapse (Fig 5C, magenta). These results suggest that ROR1 supports relapse after chemotherapy.

**Inhibition of ROR1 suppresses metastasis**


Tumor-initiating cells are crucial for the initiation and maintenance of metastasis (De Sousa *et al*, 2017). To investigate whether ROR1 contributes to metastasis, we prepared an orthotopically grafted mouse model in which S2-VP10-mCherry cells or S2-013 cells were transplanted into the pancreas. These cells formed primary tumors and metastases in the lung and mesenteric lymph nodes.

Immunohistochemical staining revealed higher expression of ROR1 in metastatic lesions than in primary tumors (Fig 6A–E). In addition, *ROR1*<sup>high</sup> metastatic foci had a higher frequency of Ki-67-positive cells than primary lesions (Fig 6F and G). To test whether ROR1 is required for the formation of metastatic lesions, we next examined the effect of *ROR1*-KD on metastatic potential using S2-VP10-mCherry-ishROR1 cells (Fig 6H). In the control group, multiple metastases were observed in the lung and mesenteric lymph nodes, whereas the number of metastatic foci was greatly reduced in the group treated with Dox from 10 days after transplantation (Fig 6I and J). These data indicate that ROR1 is critical for inducing metastasis formation by regulating tumor cell proliferation.

**Identification of an enhancer region regulating ROR1 gene expression**

As described above, we found that intratumor *ROR1*<sup>high</sup> cells in PDAC displayed various features of tumor-initiating cells. Importantly, ROR1 functionally enhances PDAC progression, such as tumor growth, relapse, and metastasis. Therefore, we considered whether the expression of ROR1 could be drug controlled and attempted to elucidate the epigenomic mechanisms governing *ROR1* gene expression.

We first analyzed histone modifications in cultured S2-VP10 cells with high ROR1 expression using a CUT&RUN assay (Skene & Henikoff, 2017) and chromatin organization using an assay for transposase-accessible chromatin by sequencing (ATAC-seq). Trimethyl histone H3 lysine 4 (H3K4me3) was enriched at the *ROR1* promoter, consistent with its actively transcribed state (Fig 7A). We also identified a putative enhancer region that opened chromatin and co-marked mono-methyl H3K4 (H3K4me1) and acetylated H3K27 (H3K27ac) at 110 kb upstream of the *ROR1* transcription start site (Fig 7A). This H3K4me1<sup>+</sup>/H3K27ac<sup>+</sup>/open chromatin region matched the active enhancer defined by the Functional Annotation of the Mammalian Genome 5 (FANTOM5) database (Fig 7A). Notably, the enrichment of H3K27ac at this region was higher in *ROR1*<sup>high</sup> cells from the S2-VP10 xenograft than in *ROR1*<sup>low</sup> cells (Fig 7B). Furthermore, ATAC-seq indicated higher chromatin accessibility of this region in *ROR1*<sup>high</sup> cells than in *ROR1*<sup>low</sup> cells (Fig 7B). To verify whether this H3K27ac<sup>+</sup> region enhances transcription from the *ROR1* promoter, we cloned both regions and placed them upstream of the luciferase reporter gene (Fig 7C). The luciferase reporter assay results showed that this candidate region enhanced reporter activity approximately six-fold compared with the promoter alone in S2-VP10 cells (Fig 7D). Together, these data indicate that *ROR1* transcription is strongly regulated by the newly identified enhancer, and that the difference in chromatin states at this region creates a divergence in *ROR1* expression levels among tumor cell subpopulations.



**Figure 3. ROR1<sup>high</sup> cells in PDAC have a high tumor-initiating capacity.**

- A Kaplan–Meier disease-specific survival curves based on *ROR1* expression levels in PDAC patients from the TCGA database ( $n = 154$ ).
- B Experimental strategy for the functional analyses of ROR1<sup>high</sup> and ROR1<sup>low</sup> cells by organoid/colony formation and tumor initiating assays.
- C FACS gating to sort ROR1<sup>high</sup> and ROR1<sup>low</sup> cells and the number of organoids or colonies ( $n = 3$  or  $n = 5$ , biological replicates). Mouse cells expressing H-2K<sup>d</sup>/H-2D<sup>d</sup> were eliminated.
- D, E Tumor initiating assay using ROR1<sup>high</sup> and ROR1<sup>low</sup> cells from the PDX#1 xenograft ( $n = 6$ ). Images of tumors (D) and tumor weights (E) are shown.
- F Tumor initiating assay using ROR1<sup>high</sup> and ROR1<sup>low</sup> cells from the S2-VP10 xenograft ( $n = 6$ ).
- G Representative images of tissue stained with H&E and AB/PAS, and for ROR1 in the PDX#1 xenograft and of tumor derived from ROR1<sup>high</sup> or ROR1<sup>low</sup> cells in the PDX#1 xenograft.

Data information: Scale bars, 1 cm (D), (F), 100  $\mu$ m (G). Graphs are presented as mean  $\pm$  s.e.m., \* $P < 0.05$ ; log-rank test (A), two-sided  $t$ -test (C), (E). Source data are available online for this figure.





Figure 4.



**Figure 4. ROR1 controls AURKB via E2F activation to promote tumor proliferation.**

- A Western blot analysis of ROR1 expression in S2-VP10-mCherry-ishROR1 cells.  $\beta$ -Actin was used as a loading control.
- B Transplantation of mCherry-labeled S2-VP10 cells expressing doxycycline (Dox)-inducible shRNA against ROR1 (S2-VP10-mCherry-ishROR1).
- C, D *In vivo* (C) and *ex vivo* (D) fluorescence imaging of S2-VP10-mCherry-ishROR1 tumors using IVIS ( $n = 3$ ).
- E Weight of tumors derived from S2-VP10-mCherry-ishROR1 cells ( $n = 3$ ).
- F Venn diagram showing ROR1-mediated biological states or processes. Hallmark gene sets are referenced in MSigDB.
- G Venn diagram to identify potential targets of ROR1 in E2F target genes.
- H The expression level of AURKB in PANC-1 cells transfected with control or ROR1 siRNA and in ROR1<sup>high</sup> or ROR1<sup>low</sup> cells from S2-VP10 and PDO#1 xenografts ( $n = 3$ ).
- I Western blot analysis of ROR1, AURKB, and  $\beta$ -actin in S2-VP10 and S2-013 cells transfected with control or ROR1 siRNA.
- J Treatment of PDO#1 and S2-VP10 organoids with DMSO (vehicle) or Aurora kinase inhibitors ( $n = 3$ , biological replicates). Totasertib, pan-Aurora kinase inhibitor; Barasertib, selective Aurora B kinase inhibitor. Representative images of organoids are shown. An area of 2,000  $\mu\text{m}^2$  and more was identified as an organoid. The area of organoids is shown in the violin plot. Black or white solid lines indicate the median value for each violin.
- K Organoid formation assay of ROR1<sup>high</sup> or ROR1<sup>low</sup> cells derived from S2-VP10 EGFP (control) or S2-VP10 AURKB-EGFP xenografts ( $n = 3$ , biological replicates). Representative images and the number of organoids are shown.
- L Western blot analysis of ROR1, AKT, phospho-AKT (Ser473), and  $\beta$ -actin in S2-VP10 and S2-013 cells transfected with control or ROR1 siRNA.
- M Heatmap showing expression of MYC and of MYC target genes that regulate RB activity in PANC-1 cells transfected with control or ROR1 siRNA.
- N Western blot analysis of ROR1, c-Myc, phospho-RB (Ser780), E2F1, and  $\beta$ -actin in S2-VP10 and S2-013 cells transfected with control or ROR1 siRNA.
- O Schematic diagram of how ROR1 enhances tumor proliferation. Created with BioRENDER.com.

Data information: Scale bars, 1 cm (D), 1 mm (J), (K). Data are presented as mean  $\pm$  s.e.m., two-sided t-test. \* $P < 0.05$ ; n.s., not significant. Source data are available online for this figure.

**Figure 5. The combination of gemcitabine and ROR1-knockdown prevents the tumor relapse.**

- A Representative immunofluorescence images of ROR1 in the PDO#1 xenograft with or without gemcitabine treatment (120 mg/kg). The boxed area is shown at high magnification in the lower right panel.
- B FACS plots of ROR1 expression in cells from the S2-VP10 xenograft with or without the administration of gemcitabine.
- C Tumor growth curve of the four groups (control, Dox only, gemcitabine only, and Dox + gemcitabine;  $n = 8$ ). The endpoint for each group is shown by a slash.
- Data information: Scale bars, 500  $\mu\text{m}$  (A). Data are presented as mean  $\pm$  s.e.m., two-sided t-test. \* $P < 0.05$ . Source data are available online for this figure.

**ROR1 is a direct target of YAP/BRD4**

We next explored the underlying mechanism for the activation of ROR1 gene expression. To identify transcription factors (TFs) that regulate the ROR1 enhancer, we analyzed the genome-wide

distribution of H3K4me1 and H3K27ac in S2-VP10 cells using a CUT&RUN assay. Using ChIP-Atlas (Oki et al, 2018), we compared the distribution pattern of 6,887 overlapping peaks (H3K4me1 and H3K27ac) found in our study with those of TFs from available datasets (Fig 8A, Appendix Fig S3, Dataset EV3, and Table EV6). Of the




Figure 6.

**Figure 6. ROR1 promotes metastasis.**


- A–C Representative images of ROR1, mCherry, and aSMA staining in the primary tumor (pancreas) (A) and metastatic lesions in the lung (B) and mesenteric lymph node (C) after orthotopic transplantation of S2-VP10-mCherry cells into the pancreas of BRJ mice.
- D, E Representative images of S2-013 orthotopic xenografts stained with H&E and for ROR1 in the pancreas (D) and mesenteric lymph node (E).
- F, G Representative images of S2-VP10 (F) or S2-013 (G) orthotopic xenografts co-staining for ROR1 and Ki-67 in the primary tumor and metastatic lesions. Dotted lines indicate the metastatic lesions.
- H The schematic diagram for evaluating the metastatic activity of *ROR1*-knockdown cells.
- I, J Representative images and quantification of metastatic foci in the lung (I) and mesenteric lymph nodes (J) after orthotopic transplantation of S2-VP10-mCherry-*ishROR1* cells into the pancreas of BRJ mice ( $n = 6$  or  $n = 8$ ).

Data information: Scale bars, 100  $\mu$ m (A)–(G), 2 mm (I), 5 mm (J). Data are presented as mean  $\pm$  s.e.m., two-sided *t*-test. \* $P < 0.05$ . Source data are available online for this figure.

202 TFs and transcription-associated antigens that showed a similar pattern with our peak data, we focused on Yes-associated protein (YAP). YAP and its close paralog, TAZ, are transcriptional regulators involved in CSC abilities such as tumorigenicity, chemoresistance, and metastasis in breast, esophageal, and hepatocellular cancers as well as in osteosarcoma (Song *et al*, 2014; Bartucci *et al*, 2015; Basu-Roy *et al*, 2015; Hayashi *et al*, 2015). Interestingly, both the *YAP1* and *WWTR1* (encoding TAZ) transcript levels were significantly and positively correlated with *ROR1* transcript levels in the pancreatic adenocarcinoma dataset TCGA-PAAD (Fig 8B and Dataset EV2). Moreover, gene set enrichment analysis revealed that intratumor *ROR1*<sup>high</sup> cells showed upregulation of YAP-regulated genes compared with *ROR1*<sup>low</sup> cells (Fig 8C). Thus, these results suggest that *ROR1*<sup>high</sup> cells have higher YAP activity than *ROR1*<sup>low</sup> cells. Analysis of publicly available ChIP-seq datasets revealed that YAP binds to the enhancer region of *ROR1* in cancer cell lines with

high *ROR1* expression (MDA-MB-231, PC-9, NCI-H2052, and SF268 cells; Fig 8D and Appendix Fig S4). In contrast, in cancer cell lines with low *ROR1* expression (MCF-7 and T-47D cells), YAP did not bind to its enhancer regions (Fig 8D and Appendix Fig S4). Using ChIP-qPCR, we detected direct binding of YAP to the *ROR1* enhancer in S2-VP10 cells (Fig 8E). In addition, siRNA knockdown of YAP/TAZ downregulated *ROR1* (Fig 8F and G). YAP/TAZ co-knockdown also reduced luciferase activity, which was under control of *ROR1* enhancer-promoter (Fig 8H). Similarly, treatment of the cells with the YAP inhibitor verteporfin reduced the expression of *ROR1* as well as the known YAP target genes such as *CTGF* and *CYR61* (Fig 8I) and the *ROR1* reporter activity (Fig 8J). Together, these results indicate that YAP directly transactivates *ROR1*.

ChIP-Atlas analyses also showed that bromodomain-containing protein 4 (BRD4), an acetylated histone-binding protein, has a highly similar genomic distribution with H3K4me1<sup>+</sup>/H3K27ac<sup>+</sup>

**Figure 7. Epigenomic analyses identify the *ROR1* gene enhancer in PDAC.**

- A, B H3K4me1, H3K4me3, H3K27ac, and open chromatin profiles around the *ROR1* gene by CUT&RUN and ATAC-seq in cultured S2-VP10 cells (A) or in *ROR1*<sup>high</sup> and *ROR1*<sup>low</sup> cells from S2-VP10 xenografts (B). The *ROR1* promoter (blue-shaded boxes) and enhancer elements (green-shaded box) of *ROR1* are indicated.
- C Schematic description of vectors used for the luciferase reporter assay to examine the regions regulating the expression of the *ROR1* gene.
- D Relative luciferase activity in S2-VP10 cells ( $n = 3$ , biological replicates).

Data information: Data are presented as mean  $\pm$  s.e.m., two-sided *t*-test. \* $P < 0.05$ . Source data are available online for this figure.




Figure 8.

**Figure 8. The YAP/BRD4 axis promotes ROR1 expression in PDAC.**

- A Strategy to identify candidate antigens overlapping the H3K4me1 (salmon pink) and H3K27ac (green) peaks in S2-VP10 using ChIP-Atlas.
- B Pearson correlation analyses of *ROR1* expression with *YAP1* and *WWTR1* expression in PDAC patient samples ( $n = 154$ ). Pearson's correlation ( $R$ ) values are indicated within each graph.
- C GSEA plot showing significant upregulation of the YAP conserved gene set in  $ROR1^{high}$  cells in the S2-VP10 xenograft or PDO#1 xenograft.
- D YAP-binding and H3K27ac profiles around the *ROR1* gene of  $ROR1^{high}$  and  $ROR1^{low}$  cell lines by ChIP-seq and CUT&RUN analyses.
- E YAP occupancy at the *ROR1* enhancer as determined by ChIP-qPCR. The known YAP targets, *CTGF* and *CYR61* promoters, were tested as positive controls, and *ROR1* intron 1 and *AFM* promoter were tested as negative controls ( $n = 4$ , biological replicates).
- F Relative expression of *ROR1* in S2-VP10 cells transfected with *YAP1* and *WWTR1* siRNA ( $n = 3$ , biological replicates). mRNA levels are normalized to that of *RPS18*.
- G Western blot analysis of YAP, TAZ, ROR1, and  $\beta$ -actin in S2-VP10 cells transfected with control or *YAP1/WWTR1* siRNA.
- H Relative luciferase activity with a reporter containing the *ROR1* enhancer-promoter region (*ROR1* reporter) in S2-VP10 cells transfected with control or *YAP1/WWTR1* siRNA ( $n = 3$ , biological replicates).
- I Relative expression of *ROR1* and YAP target genes (*CTGF* and *CYR61*) in S2-VP10 cells treated with DMSO or verteporfin (VP;  $n = 3$ , biological replicates). mRNA levels are normalized to that of *RPS18*.
- J Relative luciferase activity using the *ROR1* reporter in S2-VP10 cells treated with DMSO (vehicle) or YAP inhibitor (verteporfin;  $n = 3$ , biological replicates).
- K BRD4-binding and H3K27ac profiles around the *ROR1* gene of  $ROR1^{high}$  and  $ROR1^{low}$  cell lines detected by ChIP-seq and CUT&RUN analyses.
- L ChIP-qPCR analysis of BRD4 occupancy at the *ROR1* enhancer ( $n = 3$ , biological replicates).
- M Relative luciferase activity using the *ROR1* reporter in S2-VP10 cells treated with DMSO or BET inhibitor (JQ1;  $n = 3$ , biological replicates).
- N Co-immunoprecipitation analysis to evaluate the interaction between endogenous YAP and BRD4 in S2-VP10 cells.
- O, P Treatment of PDO#1 and S2-VP10 organoids with DMSO or JQ1 ( $n = 3$ , biological replicates). Relative expression of *ROR1* (O), representative images of organoids, and organoid area (P) are shown. mRNA levels are normalized to that of *RPS18*. The area of organoids is shown in the violin plot. Black or white solid lines indicate the median value for each violin.
- Q Schematic diagram of the regulatory mechanism of *ROR1* gene expression. Created with BioRENDER.com.

Data information: Scale bars, 1 mm (P). Data are presented as mean  $\pm$  s.e.m., \* $P < 0.05$ ; Pearson's Correlation Coefficient (B), two-sided  $t$ -test (F), (H), (I), (M), (O), and (P).

Source data are available online for this figure.

shown in our experiment (Dataset EV3 and Table EV6). BRD4 is a member of the bromodomain and extraterminal motif (BET) family (Zeng & Zhou, 2002), and BET inhibitors are rapidly being developed for clinical use because of their potent anti-tumor effects (Filipakopoulos et al, 2010; Doroshow et al, 2017). Analysis of the ChIP-seq datasets revealed the binding of BRD4 to the *ROR1* enhancer in only *ROR1*-expressing cancer cell lines (MDA-MB-231 and PC-9 cells; Fig 8K and Appendix Fig S4). ChIP-qPCR also confirmed the occupancy of BRD4 on the *ROR1* enhancer in S2-VP10 cells (Fig 8L). In addition, treatment with JQ1, one of the most established BET inhibitors, reduced *ROR1* reporter activity in S2-VP10 cells (Fig 8M). Remarkably, the co-immunoprecipitation analysis revealed that BRD4 physically interacts with YAP (Fig 8N). Treatment of PDO#1 and S2-VP10 organoids with JQ1 resulted in the downregulation of *ROR1* (Fig 8O) and the suppression of organoid growth (Fig 8P). Collectively, these data indicate that the expression of *ROR1* is regulated through the YAP/BRD4 axis (Fig 8Q).

## Discussion

Understanding how tumor-initiating cells affect cancer progression and what mechanisms promote their phenomena is crucial for developing effective therapeutic strategies against malignancies. However, the tumor-initiating cells in PDAC are not fully characterized, especially at single-cell resolution. Here, we identified  $ROR1^{high}$  tumor-initiating cells in human PDAC by demonstrating their strong capability to support tumorigenicity, chemoresistance, and metastasis. Of particular note, our scRNA-seq and bulk RNA-seq analyses revealed that  $ROR1^{high}$  cells highly overlap with the partial EMT population. In skin squamous cell carcinoma (SCC), partial EMT cells characterized by the expression of CD106 and CD51 gave rise to both epithelial- and mesenchymal-like cells

(Pastushenko et al, 2018). Another report showed that genetic ablation of the *FAT1* gene (encoding protocadherin) in skin SCC cells promoted the expression of both epithelial and mesenchymal markers (but not CD106 and CD51), and potentiated the tumor-initiating and metastatic capacities of the cells (Pastushenko et al, 2021). These previous findings indicate that the partial EMT state is associated with high cellular plasticity, and that different types of partial EMT populations exist in a tumor. In the current study, we identified *ROR1* as a cell surface marker for the partial EMT population with a high tumor-initiating potential in PDAC. In addition,  $ROR1^{high}$  cells enriched tumor-initiating cells from the well-known marker CD44v9<sup>+</sup> CSCs. Prior studies have shown that *ROR1* contributes to tumor cell survival, proliferation, migration, drug resistance, and tumorigenicity in breast and ovarian cancers (Cui et al, 2013; Zhang et al, 2014, 2019). Here, we found that *ROR1* regulates AURKB levels to enhance tumor proliferation through c-Myc and E2F activation. We also demonstrated that silencing *ROR1* inhibits relapse after chemotherapy and the development of metastatic foci *in vivo*. Our results clearly show that *ROR1* functionally enhances the tumor-initiating potential and is thus an attractive therapeutic target for PDAC.

At a low frequency,  $ROR1^{low}$  cells also generated tumors that showed hierarchical histology mimicking the original tumor and containing  $ROR1^{high}$  cells (Fig 3G). Interestingly, in  $ROR1^{low}$  cells, the *ROR1* enhancer employed the H3K4me1<sup>+</sup>/H3K27ac<sup>-</sup> poised chromatin state (Fig 7B), suggesting that the expression of *ROR1* is flexibly regulated in PDAC. These data suggest that  $ROR1^{low}$  cells may be reversibly converted into  $ROR1^{high}$  tumor-initiating cells at a low frequency, resulting in tumor seeding. Our observation is similar to that in a previous report showing that tumor cells expressing the differentiation marker keratin 20 regain their proliferative potential and convert to LGR5<sup>+</sup> CSCs in colorectal cancer (Shimokawa et al, 2017). Because different types of tumor-initiating cells have

been identified (e.g., CD44<sup>+</sup>/CD24<sup>+</sup>/ESA<sup>+</sup>, CD133<sup>+</sup>, DCLK1<sup>+</sup>, and Musashi<sup>+</sup> cells), other minor tumor-initiating cells may exist within the ROR1<sup>low</sup> population.

Current therapies for PDAC are unable to ablate tumor-initiating cells effectively. Remarkably, our *in vivo* study demonstrated that treatment with gemcitabine, a conventional therapeutic agent for PDAC, enriches intratumor ROR1<sup>high</sup> cells in PDAC. We also observed the suppression of tumor recurrence by using a combination of gemcitabine treatment and ROR1 depletion. The expansion of ROR1<sup>high</sup> tumor-initiating cells after chemotherapy might be related to efficient tumor growth during relapse. Although we have not yet clearly determined why treatment with gemcitabine enriches tumor-initiating ROR1<sup>high</sup> cells, a similar phenomenon of a chemotherapy-induced increase in the fraction of LGR5<sup>+</sup> CSCs has been reported in colorectal and liver cancers (Osawa *et al*, 2016; Cao *et al*, 2020). Eventually, these ROR1<sup>high</sup> cells may play a role in resistance against treatment and recurrence. It will be interesting to further explore the mechanisms underlying the gemcitabine-induced increase in the number of ROR1<sup>high</sup> tumor-initiating cells for anti-tumor-initiating cell therapy.

We demonstrated that the expression of *ROR1* is controlled by the enhancer with high epigenetic flexibility, leading to ROR1 heterogeneity in PDAC. Furthermore, we elucidated the mechanism of *ROR1* transactivation through the YAP/BRD4 axis. A previous study indicated that an EMT state promotes TAZ activity by inactivating Scribble, an adaptor that assembles a protein complex containing MST, LATS, and TAZ, thus leading breast cancer cells to develop CSC-like traits (Cordenonsi *et al*, 2011). Our data, therefore, suggest that YAP/TAZ signaling activated by the partial EMT state maintains ROR1<sup>high</sup> tumor-initiating cells. In addition, recent studies in breast cancer have revealed that ROR1 activates the Hippo-YAP pathway by phosphorylating and translocating HER3 into the nucleus (Li *et al*, 2017). Taken together, these findings suggest that ROR1 and YAP/TAZ may form a positive-feedback loop to maintain the ROR1<sup>high</sup> tumor-initiating cell pool. However, the mechanism by which the transactivation of ROR1 is restricted to particular cell populations, including tumor-initiating cells, is unclear since YAP hyperactivation is widespread in cancer tissues (Harvey *et al*, 2013; Johnson & Halder, 2014). Further studies are needed to clarify this mechanism.

ROR1 is an attractive target for cancer therapy because of its high expression in specific populations within tumors and its functional importance. Therefore, several therapeutic approaches against ROR1 are being explored, including ROR1-targeted CAR-T therapy (Srivastava *et al*, 2019, 2021) and antibody therapy to block signals using the monoclonal anti-ROR1 antibody cirmtuzumab (Choi *et al*, 2018). Importantly, we demonstrated that Aurora kinase inhibitors and a BET inhibitor effectively suppress the ROR1-mediated growth of PDAC organoids. BET inhibitor therapy for PDAC, including JQ1, has previously been discussed with a focus on c-Myc inhibition, stromal remodeling, and accumulation of DNA damage (Mertz *et al*, 2011; Yamamoto *et al*, 2016; Miller *et al*, 2019). We consider that ROR1-mediated suppression of c-Myc function exhibits a useful additive effect of JQ1 or other BRD4 inhibitors during ROR1<sup>high</sup> PDAC therapy. Our findings will greatly help in developing new therapeutic strategies for ROR1-driven PDAC. In addition, we previously reported an assay that detects cancer-derived ROR1-positive exosomes, which could be a basic technology for companion diagnostics (Daikuzono *et al*, 2021). ROR1 therapy with patient

stratification will be beneficial in PDAC. It would be fascinating to investigate in detail whether BET inhibitors and Aurora kinase inhibitors can eliminate ROR1<sup>high</sup> tumor-initiating cells and suppress PDAC progression, including tumor growth, relapse, and metastasis, with minimal harmful effects on normal tissues *in vivo* studies.

The major limitation of this study is the use of xenograft models in immune-deficient mice. These models mimic clinical cancer tissue with the cellular diversity and heterogeneity of tumors, which is helpful for investigating cancer biology, including the ability of tumor-initiating cells. However, there is a close relationship between the maintenance of tumor-initiating cells and immunosuppression in the tumor microenvironment (Bayik & Lathia, 2021). Therefore, future studies will need to use an immunocompetent mouse model to predict the therapeutic effects of targeting ROR1<sup>high</sup> tumor-initiating cells accurately. Although we have demonstrated that ROR1-high expressing cells in tumors play a role in the progression of PDAC in PDX and xenograft models, whether this can also occur in cancer patients requires further investigation.

## Materials and Methods

### Mice

All animal experiments in this study were performed based on protocols approved by the Institutional Animal Care and Use Committee of Kumamoto University, Japan (A2021-093). Male and female Balb/c; *Rag2*<sup>-/-</sup>/*Jak3*<sup>-/-</sup> (BRJ) mice were a gift from Dr. Seiji Okada (Kumamoto University; Okada *et al*, 2011), and we used both male and female mice for this study. Female NOD.Cg-*Prkdc*<sup>scid</sup>*Il-2rg*<sup>tm1Sug</sup>/*Shi*<sup>Jic</sup> (NOG) mice (7–10 weeks old) were obtained from the Central Institute for Experimental Animals (CIEA) and female C.B-17/*Icr*Hsd-*Prkdc*<sup>scid</sup> (SCID) mice (7–10 weeks old) were obtained from Japan SLC. All mice were housed under specific pathogen-free conditions.

### Cell lines

Human pancreatic cancer cell lines (S2-VP10, S2-013, and PANC-1) were provided by the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University. S2-VP10 and S2-013 cells were cultured in DMEM (low glucose) supplemented with 10% FBS at 37°C in 5% CO<sub>2</sub>. PANC-1 cells were cultured in RPMI-1640 supplemented with 10% FBS at 37°C in 5% CO<sub>2</sub>. L Wnt-3A cells were purchased from the American Type Culture Collection. HEK293T cells were a kind gift from Dr. Toshiro Moroishi (Kumamoto University). L Wnt3A cells and HEK293T cells were cultured in DMEM (high glucose) supplemented with 10% FBS at 37°C in 5% CO<sub>2</sub>. All cell lines were authenticated by short tandem repeat DNA profiling and were free of mycoplasma contamination. YAP inhibitor (verteporfin; Cayman, 17334) was added from the next seeding, and total RNA was extracted after 48-h incubation.

### Patient-derived xenografts (PDXs)

PDX models were established by the University of Tsukuba (Shimomura *et al*, 2018). Detailed clinical information is available in Table EV2.

### Establishment of human pancreatic cancer organoids from PDXs

Organoids were established from PDXs, based on a previous report (Seino *et al*, 2018). PDXs were washed, minced into small pieces, and digested with collagenase/dispase (Roche, 10269638001; 1 mg/ml) and DNase I (Roche, 11284932001; 1 mg/ml) in a gentleMACS Dissociator (Miltenyi Biotech) for a maximum of 60 min. After centrifugation at  $300 \times g$  for 3 min at room temperature (RT), the cells were treated with  $1 \times$  diluted RBC lysis buffer (BioLegend, 420301) for 30 s and washed three times with ice-cold PBS containing 5% fetal bovine serum (FBS). The cell pellet was resuspended in growth-factor-reduced Matrigel (Corning, 356231) and cultured in 24-well plates (50  $\mu$ l Matrigel/well) with organoid culture medium: Advanced DMEM/F-12 medium (Thermo Fisher Scientific, 12634-010) with 10 mM HEPES, 2 mM GlutaMAX-I,  $1 \times$  B27,  $1 \times$  Anti-Anti (Thermo Fisher Scientific, 15630080, 35050061, 17504044, 15240062), 10 nM Gastrin I, 1 mM N-acetylcysteine (Sigma, G9145-1MG, A9165-5G), 100 ng/ml human recombinant R-spondin-1, 100 ng/ml mouse recombinant noggin (Wako Chemicals, 181-02801, 146-08991), 50% Wnt-3A conditioned medium from L Wnt3A cells, and 500 nM A83-01 (Tocris, 2939). For the first 3 days of culture, organoids were incubated in an organoid culture medium containing 10  $\mu$ l Y-27632 (Wako Chemicals, 036-24023). The plate was incubated in 5% CO<sub>2</sub> and 20% O<sub>2</sub>. The medium was changed every 2 or 3 days. Organoids were passaged every 10–12 days.

### Organoid culture from cell line

300 cells of S2-VP10 cells were cultured in 50  $\mu$ l Matrigel per well with S2-VP10 organoid culture medium: Advanced DMEM/F-12 medium with 10 mM HEPES, 2 mM GlutaMAX-I,  $1 \times$  B27,  $1 \times$  Anti-Anti, 10 nM Gastrin I, 1 mM N-acetylcysteine, and 100 ng/ml human recombinant R-spondin-1. S2-V10 organoids were cultured in 5% CO<sub>2</sub> and 20% O<sub>2</sub>. 10  $\mu$ l Y-27632 was added in medium for the first 3 days of culture.

### Organoid formation assay

10,000 ROR1<sup>high</sup> or ROR1<sup>low</sup> sorted cells from PDX#1, 10,000 cells of dissociated PDO#1, and 300 cells of S2-VP10 were cultured per well under the respective medium conditions. Pan-Aurora inhibitor (Tozasertib; Selleck, S1048; 300 nM), Aurora B inhibitor (Barsertib; Selleck, A1147; 300 nM), and BET inhibitor (JQ1; MedChem-Express, HY13030; 100 nM) were added from the day of seeding. Images of each well were captured using a BZ-X700 microscope (Keyence) on day 30 (PDX#1), day8 or day 10 (S2-VP10 organoid and PDO#1). The organoid area was quantified using HybridCell-Count software module of BZ-X Analyzer (Keyence). An area of 2,000  $\mu$ m<sup>2</sup> and more was identified as an organoid.

### Xenotransplantation of cell lines and organoids

The cell lines and organoids were dissociated into single cells with TrypLE Express (Thermo Fisher Scientific, 12604013). For subcutaneous transplantation,  $5 \times 10^5$  cells suspended in 100  $\mu$ l complete medium (DMEM supplemented with 10% FBS) containing 50% Matrigel were injected into the flank of female BRJ mice or female SCID mice. For orthotopic transplantation,  $1 \times 10^5$  cells suspended

in 50  $\mu$ l complete medium containing 50% Matrigel were injected into the pancreas of anesthetized female BRJ mice.

### Single-cell isolation for scRNA-seq and flow cytometry analysis

Human PDAC xenografts were chopped and digested using collagenase/dispase (1 mg/ml) and DNase I (1 mg/ml) in a gentleMACS Dissociator for a maximum of 60 min. The single cell suspension was treated with  $1 \times$  diluted RBC lysis buffer and washed three times with ice-cold PBS containing 5% FBS. Cell suspensions were filtered using a 70- $\mu$ m filter to remove debris. After centrifugation, the cells were resuspended in sorting buffer with 7-AAD (BioLegend, 420404; 1:100) to gate the viable cells. The sorting gate is shown in Appendix Fig S1. Fluorescence-activated cell sorting (FACS) was conducted using a FACS Aria III and FACS SORP Aria (BD Biosciences). The data were analyzed using FlowJo (version 10.6.2, BD Biosciences).

### Library preparation for scRNA-seq

The scRNA-seq libraries were generated from sorted viable single cells using Chromium Single Cell 3' Reagent Kits v3 (10x Genomics, PN-1000092, PN-1000074, PN-120262) according to the manufacturer's instructions. The libraries were sequenced on a HiSeq X Ten sequencer (Illumina).

### scRNA-seq data analysis

In S2-VP10 xenograft, the sequencing data were mapped against the human genome (GRCh38) and quantified using the CellRanger software package (version 6.0). Raw gene counts were imported into R (version 4.0.2) and processed using the R package Seurat (version 4.0.4). Cells with  $< 1$  and  $> 30\%$  mitochondrial genes mapped,  $> 5,000$  count RNA (UMIs), and  $> 4,000$  feature RNA (expressed genes) were eliminated from the downstream analysis. After filtering, UMI counts were normalized and subjected to principal component analysis (PCA). Clustering analysis was performed using the *FindNeighbors* and *FindClusters* functions of Seurat with the parameters *FindNeighbors* (dim = 15) and *FindClusters* (resolution = 0.7). Dimensional reduction was performed by UMAP. RNA velocity analysis was carried out using Velocity.R (version 0.6) with default parameters.

scRNA-seq data of human PDAC were obtained from Peng *et al* (2019). FASTQ files were downloaded from the Genome Sequence Archive (CRA001160) and the data of T20 (CRR241804) was used for analysis. The sequencing data were mapped to the human genome (GRCh38) and quantified using the CellRanger software package (version 7.0). Cells with  $> 25\%$  mitochondrial genes mapped,  $> 5,000$  count RNA (UMIs) were eliminated from the downstream analysis using Seurat. Moreover, cells expressing *KRT18* or *KRT8* were selected (1,739 cells) and re-normalize with SCTransform. Other parameters are as follows: *FindNeighbors* (dim = 20) and *FindClusters* (resolution = 0.5).

### Flow cytometry

After dispersal of the xenografts into single cells, the cell pellet was suspended in sorting buffer (D-PBS with 2% FBS, 1 mM EDTA, and

25 mM HEPES). The cells were first incubated with anti-ROR1 antibody (BD Biosciences, 564464) and/or anti-CD44v9 antibody (Cosmo Bio, LKG-M003) at 2 µg/ml and incubated on ice for 30 min. After washing, the cells were stained with goat anti-mouse IgG<sub>2b</sub> labeled Alexa Fluor 647 (Thermo Fisher Scientific, A21242; 1:1,000) or goat anti-rat IgG (H + L) labeled PE (Thermo Fisher Scientific, A10545; 1:200) and PE/Cy7-labeled anti-H-2K<sup>d</sup>/H-2D<sup>d</sup> (BioLegend, 114718; 1:50) on ice for 30 min in the dark. After washing twice, the cells were resuspended in sorting buffer with 7-AAD (BioLegend) to gate the viable cells. The sorting gate is shown in Appendix Fig S2. Flow cytometric analysis was performed using FACSVerse (BD Biosciences), and FACS was conducted using a FACS Aria III and FACS SORP Aria (BD Biosciences).

### RNA-seq analysis

For the S2-VP10 xenograft, RNA was extracted from sorted ROR1<sup>low</sup> and ROR1<sup>high</sup> cells using a MagMAX-96 Total RNA Isolation Kit (Thermo Fisher Scientific, AM1830), and 1 ng of RNA was used for the reverse transcription reaction using SMART-seq HT (Takara, 634455). For the PDO xenograft, ROR1<sup>low</sup> and ROR1<sup>high</sup> cells were collected directly into CDS Sorting Solution by FACS sorting, then cDNA was synthesized without RNA purification using SMART-seq HT (Takara). For the PANC-1 cells, RNA was extracted using total RNA was extracted using a ReliaPrep RNA Miniprep System (Promega, Z6012), and 1 ng of RNA was used for the reverse transcription reaction using SMART-seq HT. The RNA-seq library was prepared using a Nextera XT Library Prep Kit (Illumina, FC-131-1024, FC-131-1001) and sequenced using a HiSeq X Ten sequencer (Illumina). RNA-seq reads were aligned to a human transcriptome (GRCh38) and quantified by Salmon (Patro *et al*, 2017; version 1.3.0) with default settings. Differential expression testing was performed with DESeq2 (Love *et al*, 2014; version 1.28.1). A *P*-value threshold of < 0.05 was used to determine differentially expressed genes. Gene set enrichment analysis was performed using GSEA (version 4.0.3; Broad Institute) with H hallmark gene sets and CORNENSI\_YAP\_CONSERVED\_SIGNATURE (M2871) in the Molecular Signatures Database. The heat maps were drawn using the ggplot2 R package.

### Real-time quantitative PCR

For cultured S2-VP10 cells, total RNA was extracted using a ReliaPrep RNA Miniprep System (Promega, Z6012), and cDNA was synthesized using a High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Thermo Fisher Scientific, 4374967). Real-time qPCR reactions were performed on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) using PowerUP SYBR Green Master Mix (Thermo Fisher Scientific, A25742). Samples were run in three biological replicates, and mRNA levels were normalized to *RPS18*. The primers used are listed in Table EV8.

### Histology and immunostaining

Xenografts were isolated and immediately fixed in 4% paraformaldehyde (Nakalai Tesque, 09154-56) at 4°C for 16 h. Paraffin-embedded samples were cut into 4-µm sections and used for histological analysis. Hematoxylin and eosin (H&E) staining and alcian

blue and periodic acid-Schiff (AB/PAS) staining were performed using standard protocols. For immunohistochemistry (IHC), antigen retrieval was carried out in an autoclave (2100 Retriever, Aptum Biologics) using 0.01 M citrate buffer (pH 7.0). After treating with 3% H<sub>2</sub>O<sub>2</sub> to block endogenous peroxidase activity, sections were incubated in Tris-buffered saline/0.1% Tween-20 (TBS-T) containing 5% goat serum (Jackson Immuno Research Laboratories, 005-000-001) to block non-specific binding. The following primary antibodies were used: rabbit anti-ROR1 (Thermo Fisher Scientific, PA5-50830; 1:50), mouse anti-pan cytokeratin (Nichirei, 412811; 1:2), rabbit anti-RFP (MBL, PM005; 1:400), mouse anti-Ki67 (DAKO, M7240; 1:200), and mouse anti-alpha smooth muscle actin (Thermo Fisher Scientific; 14-9760-82; 1:400). The secondary antibodies were horseradish peroxidase-conjugated goat anti-rabbit IgG antibodies (Nichirei, 424141) for HRP-IHC and visualized using a Liquid DAB+ Substrate Chromogen System (DAKO, K3468), or Alexa Fluor Plus 488- or 555-conjugated goat anti-mouse, rabbit IgG antibodies (Thermo Fisher Scientific, A32723, A32731, A32727, A32732; 1:1,000) for immunofluorescence. Nuclei were counterstained with hematoxylin or DAPI (Dojindo, 340-07971). All slides were imaged using a BZ-X700 fluorescence microscope or VS120 fluorescence virtual slide microscope (Olympus).

### Colony formation assay

For 2,000 sorted cells, 20 µl of 50% Matrigel containing complete medium was added and mixed gently on ice. A 96-well plate was chilled on ice and coated with 25 µl of cell-free 50% Matrigel. After polymerization of the coated Matrigel at 37°C for 10 min, the cell mixture was overlaid at a density of 2,000 cells per well. Half the volume of the medium was changed every 2–3 days. Images of each well were captured using a BZ-X700 microscope on day 8.

### Tumor-initiating assay

Sorted ROR1<sup>low</sup> and ROR1<sup>high</sup> cells from xenografts were mixed with 50% Matrigel containing complete medium. The cell suspension was subcutaneously injected into the flank of female BRJ mice or female NOG mice. The resulting tumors were harvested after 56 days (PDO#1 xenograft) or 27 days (S2-VP10 xenograft) post-injection.

### Lentivirus preparation and establishment of stable cell lines

To generate lentivirus-based doxycycline inducible shRNA constructs against *ROR1*, the shRNA sequences (5'-CTCATTTAGCAGACATCGCAA-3' (shRNA-1) and 5'-CTTTACTAGGAGACGCCAATA-3' (shRNA-2) (Zhang *et al*, 2012b)) were inserted into EZ-Tet-pLKO-Puro vector (Addgene, 85966), respectively. The preparation of lentivirus has been described previously (Daikuzono *et al*, 2021). Cells were infected with the two lentiviral shRNAs against *ROR1* and selected after 48 h with 0.5 µg/ml puromycin (Nakalai Tesque, 29455-12). To induce the expression of shRNA *in vitro*, 1 µg/ml doxycycline (Tokyo Chemical Industry, D4116) was added to the cells. For *in vivo* studies, mice were given drinking water supplemented with 2 mg/ml doxycycline (Tokyo Chemical Industry) and 5% sucrose (Wako Chemicals, 196-00015). For *AURKB* overexpression, *AURKB* cDNA derived from S2-VP10 cells was subcloned into



pJEM1 lentiviral vector (Addgene, 19319). As a control, we used the pLJM1-EGFP vector. Cells were labeled with mCherry using the pLV-mCherry vector (Addgene, 36084).

### **In vivo fluorescence imaging of tumor growth**

*In vivo* fluorescence imaging was performed using an IVIS SPECTRUM (Caliper Life Sciences). The mCherry-labeled tumor-bearing mice were anesthetized with isoflurane and imaged. The filter settings were Ex = 570 nm, Em = 620 nm. Data were quantified with Living Imaging software (version 4.3.1).

### **Western blotting**

Cells were lysed with RIPA buffer (Wako Chemicals, 182-02451) containing cOmplete protease inhibitor cocktail (Roche, 05056489001) and PhosSTOP phosphatase inhibitor cocktail (Roche, 05056489001). Whole-cell lysate was loaded and separated on a 7.5% polyacrylamide gel and transferred onto a PVDF membrane (Merck Millipore, IPVH07850). Membranes were blocked with PVDF Blocking Reagent for Can Get Signal (Toyobo, NYPBR01) and then incubated with primary antibody in Can Get Signal Solution 1 (Toyobo, NKB-101). The following primary antibodies were used: mouse anti- $\beta$ -actin (Sigma, A1978; 1:10,000), rabbit anti-ROR1 (Cell Signaling Technology, 16450; 1:250), rabbit anti-AKT (Cell Signaling Technology, 4691; 1:1,000), rabbit anti-phospho-AKT (Ser473; Cell Signaling Technology, 9271; 1:1,000), rabbit anti-Aurora B (Abcam, ab2254; 1:1,000), rabbit anti-YAP (Cell Signaling Technology, 14074; 1:1,000), rabbit anti-TAZ (Cell Signaling Technology, 72804; 1:1,000), rabbit anti-BRD4 (Cell Signaling Technology, 13440; 1:1,000), rabbit anti-c-Myc (Cell Signaling Technology, 5605; 1:1,000), rabbit anti-phospho-Rb (Ser795; Novus, 82176; 1:1,000), and mouse anti-E2F1 (Santa Cruz Biotechnology, 251; 1:500). Signals were detected by HRP-conjugated anti-rabbit or mouse antibody (Cell Signaling Technology, 7074, 7076; 1:1,000) in Can Get Signal Solution 2 (Toyobo) and visualized with ECL Prime Western Blotting Detection Reagent (GE Healthcare, RPN2232). Chemiluminescent signals were detected using a LAS-3000 Imaging System (GE Healthcare).

### **RNA interference**

Reverse transfection of siRNA was performed using lipofectamine RNAiMAX (Thermo Fisher Scientific, 13778150) with a final siRNA concentration of 10 nM. Cells were harvested after 48-h incubation. The siRNAs were purchased from Qiagen and Dharmacon (Qiagen, negative control siRNA: 1027280, siROR1: SI00071295; Dharmacon, negative control siRNA: D-001810-01, siYAP1#3: J-012200-07-0002, siWWTR1#2: J-016083-06-0002).

### **Xenograft experiments with recurrent and metastasis models**

For the recurrence experiments, mice implanted with S2-VP10 cells (14 days post-implantation) or PDO#1 (18 days post-implantation) were given gemcitabine (Pfizer, 4987114700506; 120 mg/kg) intraperitoneally three times daily for 3 days. For flowcytometric analysis and IHC analysis, xenografts were harvested 1 day after the last administration. Tumor volume (Tv) measurements were made every day ( $Tv [mm^3] = (length [mm] \times width [mm]^2)/2$ ). In the

experiment of treatment with Dox, mice were separated experimental groups of randomize.

For the metastasis experiments, mice implanted with S2-VP10 cells or S2-013 cells orthotopically into the pancreas were sacrificed at 21 days post-implantation. The metastatic foci in the isolated lung and mesentery were counted using a SZX12 stereo microscope (Olympus). To observe tissue deeply, lung samples were decolorized using CUBIC-Cancer method (Kubota *et al*, 2017). In the experiment of treatment with Dox, mice were separated experimental groups of randomize.

### **CUT&RUN**

CUT&RUN was performed using a CUT&RUN Assay Kit (Cell Signaling Technology, 86652) with a modification of the manufacturer's protocol. Between 28,000 and 50,000 collected cells were washed and bound to activated concanavalin A-coated magnetic beads. After permeabilization, the bead-cell complex was incubated with antibody at RT for 2 h on a nutator, with gentle tapping every 20 min. After washing, the beads were resuspended in pAG-MNase and incubated at 4°C for 1 h, with gentle tapping every 20 min. After washing, the beads in digitonin buffer were chilled in ice water bath (0°C), then pre-cooled calcium chloride was added to activate MNase for 30 min. Enriched DNA fragments were purified by phenol–chloroform–isoamyl alcohol/ethanol extraction. The following antibodies were used: rabbit anti-mono-methylated histone H3K4 (Abcam, ab8895; 1  $\mu$ g), rabbit anti-tri-methylated histone H3K4 (Millipore, 07-473; 1  $\mu$ g), rabbit anti-acetylated histone H3K27 (Cell Signaling Technology, 8173; 1:100), and rabbit isotype control IgG (BioLegend, 910805; 1  $\mu$ g). The CUT&RUN library was prepared using a NEBNext Ultra II DNA Library Prep Kit for Illumina (New England Biolabs, E7645, E7710) as previously reported (Zhu *et al*, 2019). High-throughput sequencing was performed using a NextSeq 500 Sequencer with 75-bp single-end reads. Qualified reads were aligned to the human genome (GRCh37) using Bowtie2 (Langmead & Salzberg, 2012; version 2.3.4.1). Duplicate reads were removed. The number of unique reads was normalized to spike-in yeast DNA (sacCer3). The final number of mapped reads and scaling factors are listed in Table EV7. Peak detection was performed using MACS2 (Zhang *et al*, 2008; version 2.2.7.1) with default parameters. The overlapping peaks between H3K4me1 and H3K27ac were obtained using the bedtools intersect function (version 2.30.0). CUT&RUN data were converted to bigwig files by bamCoverage (in the deepTools package (Ramírez *et al*, 2016), version 3.5.1) using the parameters `--scaleFactor<each sample>--binSize 10`, then visualized using Integrative Genome Viewer (IGV). Enrichment analysis of the overlapping peaks (H3K4me1 and H3K27ac) with other TFs was performed using ChIP-Atlas with the following parameters: [Experiment type] ChIP TFs and others; [Cell type Class] Pancreas, Breast, Lung; [Threshold for Significance] 100. The aggregation plot was drawn using computeMatrix and plotHeatmap of deepTools.

### **ATAC-sequencing**

ATAC-sequencing was performed with modifications based on a previous report (Corces *et al*, 2017). The collected cells (2D cultured: 50,000 cells, sorted from xenografts: 15,000 cells) were suspended in 50  $\mu$ l of cold cell lysis buffer (10 mM Tris–HCl pH 7.5,

10 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.1% NP-40, 0.1% Tween-20, 0.01% digitonin in water) by pipetting three times and incubated on ice for 3 min. After lysis, 1 ml wash buffer (10 mM Tris–HCl pH 7.5, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, 0.1% Tween-20) was added, and the reaction mixture was centrifuged at 500 × g for 10 min at 4°C to collect nuclei. The supernatant was removed, and the nuclei were resuspended in 50 µl transposition mixture (25 µl 2× Tagmentation buffer (Diagenode, C01019043), 2.5 µl Tagmentase loaded (Diagenode, C01070012), 0.5 µl digitonin (final concentration 0.01%), 0.5 µl Tween-20 (final concentration 0.1%), 16.5 µl PBS, and 5 µl nuclease-free water). The transposition reaction mixture was incubated for 30 min at 37°C in a block incubator. The transposition DNA fragments were purified using a MinElute PCR Purification Kit (Qiagen, 28006) and eluted in 20 µl buffer EB. Transposed DNA fragments were amplified by combining the following: 20 µl transposed DNA, 2.5 µl of 25 µM PCR Primer 1 (i5), 2.5 µl of 25 µM PCR Primer 2 (barcoded, i7), and 25 µl KAPA HiFi HS Ready Mix (Kapa Biosystems, KK2601). The following thermal cycler conditions were used: 72°C for 5 min, 98°C 30 s, followed by 11 cycles (50,000 cells) or 12 cycles (15,000 cells) of 98°C 10 s, 63°C 30 s, and 72°C 1 min. The amplified library was purified using a 1.8× volume of AMPure XP beads (Beckman Coulter, A63880) and eluted in 20 µl buffer EB. To remove large-size fragments (> 1,000 bp), a 0.55× volume (11 µl) of SPRIselect (Beckman Coulter, B23317) was added to the purified library. Following 2-min incubation at room temperature, the reaction tube was placed in a magnetic rack for 5 min. After the liquid appeared completely clear, 31 µl of the supernatant was transferred to a new tube and 25 µl SPRIselect (final volume of 1.8× based on the initial reaction volume) was added to the sample. After 2-min incubation at room temperature, the library was washed twice with 80% ethanol and eluted in 20 µl buffer EB. Library size distributions were checked using an Agilent 2200 TapeStation (Agilent Technologies). High-throughput sequencing and data analysis were performed by the same method as CUT&RUN. ATAC-seq data were converted to bigwig files using bamCoverage with default parameters. The primers used are listed in Table EV8.

#### FANTOM5 enhancer data

Human enhancers were searched using FANTOM5 Human Enhancers Selector ([https://slidebase.binf.ku.dk/human\\_enhancers/selector](https://slidebase.binf.ku.dk/human_enhancers/selector)) using the parameters Genes ROR1, Upstream 1,000,000 bp, and Downstream 150,000 bp.

#### Luciferase reporter assay

S2-VP10 genomic DNA was extracted using a DNeasy Blood & Tissue Kit (Qiagen, 69504). The promoter and enhancer candidate regions of ROR1 were amplified by PCR using KOD -Plus- Neo (Toyobo, KOD-401) and subcloned into the pGL3 luciferase reporter vector (Promega, E1751; Fig 7C). The primers used are listed in Table EV8. All inserts were confirmed by sequencing. For transient transfection, S2-VP10 cells were co-transfected with 0.5 µg of each luciferase reporter plasmid and 1 ng of pRL-SV40 (Promega, E2231) or pRL-TK (Promega, E2241) the day after plating (3.45 × 10<sup>4</sup> cells/well in a 24-well plate) using FuGENE HD (Promega, E2312). After 48-h incubation, the cells were harvested and luciferase was measured using a Dual-Luciferase Reporter Assay System (Promega,

E1980). The promoter and enhancer activity were calculated by the ratio of firefly/renilla luciferase activity.

#### ROR1 and YAP/TAZ gene expression analysis (TCGA database)

Gene expression data were downloaded from TCGA (TCGA-PAAD, accessed the GDC data portal [<https://portal.gdc.cancer.gov/>], retrieved on March 22, 2021) (Dataset EV2). ROR1 and YAP1/WWTR1 expression were extracted and evaluated by Pearson correlation analysis. Correlation coefficients and *P*-values are reported.

#### ChIP-seq data analysis

Bigwig files were retrieved from the GEO database (GSE66081, GSE131687, GSE61852, GSE125609, GSE116879, GSE89128, GSE123286, and GSE63584). ROR1 gene expression data were downloaded from the CCLE database. All data were visualized using IGV.

#### ChIP-qPCR

About 5 × 10<sup>6</sup> S2-VP10 cells were used to detect YAP and BRD4 enrichment. Cells were crosslinked with 1% formaldehyde for 10 min at RT, then equilibrated with 0.135 M glycine. Cells were lysed in lysis buffer (5 mM PIPES [pH 8.0], 85 mM KCl, 5% NP-40). Isolated nuclei were suspended in low-salt SDS buffer (0.1% SDS, 10 mM EDTA, 50 mM Tris–HCl [pH 8.0]) and sonicated to fragment the chromatin using a Bioruptor UCD-300 (high, 30 s on/30 s off, 20 min, Cosmo Bio). After preclearing at 4°C for 1 h, chromatin fragments were incubated at 4°C overnight with antibodies for YAP (Cell Signaling Technology; 1:100) or BRD4 (Cell Signaling Technology; 1:100). Antibody/antigen complexes were recovered with Dynabeads M-280 sheep anti-rabbit IgG (Thermo Fisher Scientific, 11203D). Beads with DNA fragments were washed once with RIPA buffer (50 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate), twice with high salt RIPA buffer (50 mM Tris–HCl, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate), once with LiCl wash buffer (10 mM Tris–HCl, 250 mM LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate), and twice with TE buffer. The washed beads with DNA fragments were resuspended in ChIP elution buffer (0.5% SDS, 10 mM Tris–HCl, 5 mM EDTA, 300 mM NaCl) and incubated at 65°C for 6 h to reduce the crosslinks. Enriched DNA fragments were purified by phenol–chloroform–isoamyl alcohol/ethanol extraction and subjected to qPCR analysis. The primers used are listed in Table EV8.

#### Co-immunoprecipitation of endogenous nuclear proteins

About 1 × 10<sup>7</sup> S2-VP10 cells were used for the analysis. Proteins were crosslinked using 1 mM dithiobis (succinimidyl propionate; DSP; Dojindo, D629) to increase the stability of the protein–protein complexes. The cells were rinsed with ice-cold PBS and harvested using a cell scraper. The nuclei were isolated in nuclear extraction buffer (20 mM HEPES-KOH (pH 8.0), 10 mM KCl, 0.1% NP-40, 20% glycerol, freshly added protease inhibitors) at 4°C for 15 min. After centrifugation and discarding the supernatant, the nuclear pellet was lysed in hypertonic buffer (20 mM HEPES, 400 mM NaCl, 1 mM EDTA, 0.5% NP-40, freshly added protease inhibitors) and

sonicated using a Bioruptor UCD-300 (high, 30 s on/30 s off, 10 min). The nuclear lysates were centrifuged at 18,000 × g for 10 min at 4°C, and the supernatant was collected and diluted in 150 mM NaCl. After preclearing for 1 h at 4°C, the lysates were incubated at 4°C for 5 h with antibodies for BRD4 (Cell Signaling Technology; 1:100). Antibody/antigen complexes were recovered using Dynabeads Protein A/G (Thermo Fisher Scientific, DB10001, DB10003) for 1 h at 4°C. The immunocomplex was washed four times with wash buffer (20 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, freshly added protease inhibitors). Proteins were eluted in SDS sample buffer with 2-mercaptoethanol at 95°C for 5 min and subjected to western blot analysis.

### Survival analysis (TCGA database)

The gene expression data and clinical data were downloaded from TCGA (TCGA-PAAD, accessed the GDC data portal [<https://portal.gdc.cancer.gov/>], retrieved on March 22, 2021; Dataset EV2). The association between the expression of *ROR1* and patient disease-specific survival was examined by the Kaplan–Meier method.

### Statistics

Pairwise comparisons were performed using an unpaired two-tailed Student's *t*-test. Results are presented as the mean ± s.e.m. (standard error of the mean). A *P*-value less than 0.05 was considered statistically significant. Statistical analysis was performed using Prism 8 (GraphPad Software Inc.).

### Human samples

Clinical samples were obtained from patients at University of Tsukuba Hospital with written informed consent after approval by the ethical committees. All human experiments were approved by University of Tsukuba (BBC2021-006) and Kumamoto University (Genome #409).

## Data availability

The accession number for the scRNA-seq, RNA-seq, CUT&RUN, and ATAC-seq data in this study is GEO: GSE191204 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE191204>).

- RNA-seq data: Gene Expression Omnibus GSE191198 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE191198>)
- scRNA-seq data: Gene Expression Omnibus GSE191193 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE191193>)
- CUT&RUN data: Gene Expression Omnibus GSE191202 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE191202>)
- ATAC-seq data: Gene Expression Omnibus GSE191203 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE191203>)

**Expanded View** for this article is available [online](#).

### Acknowledgements

We thank M. Yamamoto and M. Muramatsu (Kumamoto University) for insightful discussions, T. Takahashi (Aichi Cancer Center) for useful advices,

Daikuzono, Y Ikeda, Y. Fukuchi (Kumamoto University), and S. Fujimura (Liaison Laboratory Research Promotion Center) for technical assistance, and K. Kurokawa (Devers Eye Institute) and S. Watanabe (Kumamoto University) for helpful comments on the manuscript. We thank T. Moroishi (Kumamoto University) for critical reading of this manuscript and providing the HEK293T cells. We also thank S. Okada (Kumamoto University) for providing the *Rag2/Jak3* double-deficient mice. We also thank The NIBB Genome Informatics Training Course (GITC; The National Institute for Basic Biology) for teaching the basics of NGS analysis. We also thank T. Takeuchi and H. Nishiyama (Tsukuba Human Tissue Bank Center, University of Tsukuba Hospital) for support in providing the resources. EZ-Tet-pLKO-Puro was a gift from Cindy Miranti (Frank et al, 2017). pMD2.G and psPAX2 were a gift from Didier Trono. pLJM1-EGFP was a gift from Prof. David Sabatini. pLV-mCherry was a gift from Pantelis Tsoulfas. This work was supported by grant-in-aid for Scientific Research (19H03711, 20H03691, 22K20921), by JST SPRING (JPMJSP2127), and by grant from Center for Metabolic Regulation of Health Aging (CMHA).

### Author contributions

**Masaya Yamazaki:** Conceptualization; data curation; formal analysis; supervision; funding acquisition; validation; investigation; visualization; methodology; writing – original draft; project administration. **Shinjiro Hino:** Methodology; writing – review and editing. **Shingo Usuki:** Formal analysis. **Yoshihiro Miyazaki:** Resources. **Tatsuya Oda:** Resources. **Mitsuyoshi Nakao:** Writing – review and editing. **Takaaki Ito:** Supervision; funding acquisition; writing – review and editing. **Kazuya Yamagata:** Supervision; funding acquisition; writing – review and editing.

### Disclosure and competing interests statement

The authors declare that they have no conflict of interest.

## References

- Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci USA* 100: 3983–3988
- Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ et al (2021) Acquired resistance to KRAS G12C inhibition in cancer. *N Engl J Med* 384: 2382–2393
- Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W et al (2014) DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. *Gastroenterology* 146: 245–256
- Barker N, Ridgway RA, Van Es JH, Van De Wetering M, Begthel H, Van Den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 457: 608–611
- Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Di Benedetto A, Todaro M, Stassi G, Sperati F et al (2015) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. *Oncogene* 34: 681–690
- Basu-Roy U, Bayin NS, Rattanakor K, Han E, Placantonakis DG, Mansukhani A, Basilico C (2015) Sox2 antagonizes the hippo pathway to maintain stemness in cancer cells. *Nat Commun* 6: 1–14
- Battle E, Clevers H (2017) Cancer stem cells revisited. *Nat Med* 23: 1124–1134
- Bayik D, Lathia JD (2021) Cancer stem cell–immune cell crosstalk in tumour progression. *Nat Rev Cancer* 21: 526–536

- Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 3: 730–737
- Boumahdi S, de Sauvage FJ (2020) The great escape: tumour cell plasticity in resistance to targeted therapy. *Nat Rev Drug Discov* 19: 39–56
- Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N et al (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* 575: 217–223
- Cao W, Li M, Liu J, Zhang S, Noordam L, Verstegen MMA, Wang L, Ma B, Li S, Wang W et al (2020) LGR5 marks targetable tumor-initiating cells in mouse liver cancer. *Nat Commun* 11: 1961
- Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH, Yuan CC (2009) Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. *Virchows Arch* 455: 431–440
- Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E et al (2018) Phase I trial: Cirmuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia. *Cell Stem Cell* 22: 951–959
- Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells – perspectives on current status and future directions: AACR workshop on cancer stem cells. *Cancer Res* 66: 9339–9344
- Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, Satpathy AT, Rubin AJ, Montine KS, Wu B et al (2017) An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. *Nat Methods* 14: 959–962
- Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A et al (2011) The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. *Cell* 147: 759–772
- Cui B, Zhang S, Chen L, Yu J, Widhopf GF, Fecteau JF, Rassenti LZ, Kipps TJ (2013) Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. *Cancer Res* 73: 3649–3660
- Daikuzono H, Yamazaki M, Sato Y, Takahashi T, Yamagata K (2021) Development of a DELFIA method to detect oncofetal antigen ROR1-positive exosomes. *Biochem Biophys Res Commun* 578: 170–176
- Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM et al (2007) Phenotypic characterization of human colorectal cancer stem cells. *Proc Natl Acad Sci USA* 104: 10158–10163
- De Sousa E, Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z et al (2017) A distinct role for Lgr5 + stem cells in primary and metastatic colon cancer. *Nature* 543: 676–680
- Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, Breart B, Foreman O, Bainbridge TW, Castiglioni A et al (2020) Single-cell RNA sequencing reveals stromal evolution into LRRC15 + myofibroblasts as a determinant of patient response to Cancer immunotherapy. *Cancer Discov* 10: 232–253
- Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. *Nat Rev Mol Cell Biol* 20: 69–84
- Doroshov DB, Eder JP, LoRusso PM (2017) BET inhibitors: a novel epigenetic approach. *Ann Oncol* 28: 1776–1787
- Ellen TP, Ke Q, Zhang P, Costa M (2008) NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. *Carcinogenesis* 29: 2–8
- Filippakopoulos P, Qi J, Piccaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I et al (2010) Selective inhibition of BET bromodomains. *Nature* 468: 1067–1073
- Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J, Koehlein CS, Zimdahl B, Yano M, Kopp JL et al (2016) Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. *Nature* 534: 407–411
- Frank SB, Schulz W, Miranti CK (2017) A streamlined method for the design and cloning of shRNAs into an optimized dox-inducible lentiviral vector. *BMC Biotechnol* 17: 1–10
- Harvey KF, Zhang X, Thomas DM (2013) The hippo pathway and human cancer. *Nat Rev Cancer* 13: 246–257
- Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto D et al (2015) An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. *Cancer Res* 75: 4985–4997
- Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. *Cell Stem Cell* 1: 313–323
- Johnson R, Halder G (2014) The two faces of hippo: targeting the hippo pathway for regenerative medicine and cancer treatment. *Nat Rev Drug Discov* 13: 63–79
- Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH et al (2016) Pancreatic cancer. *Nat Rev Dis Primers* 2: 1–23
- Kubota SI, Takahashi K, Nishida J, Tainaka K, Miyazono K, Ueda Correspondence HR (2017) Whole-body profiling of Cancer metastasis with single-cell resolution. *Cell Rep* 20: 236–250
- La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, Lidschreiber K, Kastri ME, Lönnberg P, Furlan A et al (2018) RNA velocity of single cells. *Nature* 560: 494–498
- Langmead B, Salzberg SL (2012) Fast gapped-read alignment with bowtie 2. *Nat Methods* 9: 357–359
- Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. *Cell* 141: 1117–1134
- Lens SMA, Voest EE, Medema RH (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. *Nat Rev Cancer* 10: 825–841
- Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. *Cancer Res* 67: 1030–1037
- Li C, Wang S, Xing Z, Lin A, Liang K, Song J, Hu Q, Yao J, Chen Z, Park PK et al (2017) A ROR1-HER3-lncRNA signalling axis modulates the hippo-YAP pathway to regulate bone metastasis. *Nat Cell Biol* 19: 106–119
- Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15: 1–21
- Lytle NK, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, Schürch CM, Hamilton M, Robertson N, Lin W et al (2019) A multiscale map of the stem cell state in pancreatic adenocarcinoma. *Cell* 177: 572–586
- Magee JA, Piskounova E, Morrison SJ (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. *Cancer Cell* 21: 283–296
- Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, Shang Y, Zhang L, Li X, Zhang Y et al (2022) KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. *Cell Discov* 8: 1–14
- Marusyk A, Janiszewska M, Polyak K (2020) Intratumor heterogeneity: the Rosetta stone of therapy resistance. *Cancer Cell* 37: 471–484
- Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. *Proc Natl Acad Sci USA* 108: 16669–16674

- Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ (2019) The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. *EBioMedicine* 44: 419–430
- Mizrahi JD, Surana R, Valle JW, Shroff RT (2020) Pancreatic cancer. *Lancet* 395: 2008–2020
- O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 445: 106–110
- Okada S, Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H, Suzu S (2011) Comparative study of human hematopoietic cell engraftment into Balb/c and C57BL/6 strain of rag-2/Jak3 double-deficient mice. *J Biomed Biotechnol* 2011: 539748
- Oki S, Ohta T, Shioi G, Hatanaka H, Ogasawara O, Okuda Y, Kawaji H, Nakaki R, Sese J, Meno C (2018) Ch IP-atlas: a data-mining suite powered by full integration of public Ch IP-seq data. *EMBO Rep* 19: e46255
- Osawa H, Takahashi H, Nishimura J, Ohta K, Haraguchi N, Hata T, Yamamoto H, Mizushima T, Takemasa I, Doki Y et al (2016) Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer. *Br J Cancer* 114: 1251–1260
- Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S et al (2018) Identification of the tumour transition states occurring during EMT. *Nature* 556: 463–468
- Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, Impens F, Van Haver D, Opitz M, Thery M et al (2021) Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. *Nature* 589: 448–455
- Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C (2017) Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods* 14: 417–419
- Peng J, Sun BF, Chen CY, Zhou JY, Chen YS, Chen H, Liu L, Huang D, Jiang J, Cui GS et al (2019) Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. *Cell Res* 29: 725–738
- Puram SV, Tirosh I, Parkh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS et al (2017) Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell* 171: 1611–1624
- Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dündar F, Manke T (2016) deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res* 44: W160–W165
- Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, Robertson AG, Cherniack AD, Gupta M, Getz G et al (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell* 32: 185–203
- Reid MD, Basturk O, Thirabanjasak D, Hruban RH, Klimstra DS, Bagci P, Altinel D, Adsay V (2011) Tumor-infiltrating neutrophils in pancreatic neoplasia. *Mod Pathol* 24: 1612–1619
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. *Nature* 445: 111–115
- Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, Ohta Y, Matano M, Nanki K, Kawasaki K et al (2018) Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. *Cell Stem Cell* 22: 454–467
- Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. *Cell* 138: 822–829
- Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat Rev Clin Oncol* 14: 611–629
- Shimokawa M, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, Date S, Sugimoto S, Kanai T, Sato T (2017) Visualization and targeting of LGR5 + human colon cancer stem cells. *Nature* 545: 187–192
- Shimomura O, Oda T, Tateno H, Ozawa Y, Kimura S, Sakashita S, Noguchi M, Hirabayashi J, Asashima M, Ohkohchi N (2018) A novel therapeutic strategy for pancreatic cancer: targeting cell surface glycan using rBC2LC-N lectin–drug conjugate (LDC). *Mol Cancer Ther* 17: 183–195
- Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. *Cancer Res* 63: 5821–5828
- Skene PJ, Henikoff S (2017) An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. *Elife* 6: e21856
- Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B et al (2014) Hippo coactivator YAP1 upregulates SOX9 and endows esophageal Cancer cells with stem-like properties. *Cancer Res* 74: 4170–4182
- Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, Smythe KS, Dudakov JA, Pierce RH, Rader C et al (2019) Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to Normal tissues and enables selective tumor targeting. *Cancer Cell* 35: 489–503
- Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, Garrison SM, Specht JM, Lee SM, Amezcua RA et al (2021) Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. *Cancer Cell* 39: 193–208
- Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoerckius M, Smibert P, Satija R (2019) Comprehensive integration of single-cell data. *Cell* 177: 1888–1902
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* 102: 15545–15550
- Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G (2006) Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. *Mol Cancer Ther* 5: 2905–2918
- Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ et al (2022) Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. *J Med Chem* 65: 3123–3133
- Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L et al (2020) Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. *Nature* 577: 421–425
- Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H et al (2012) NKX2-1/TITF1/TF1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. *Cancer Cell* 21: 348–361
- Yamamoto K, Tateishi K, Kudo Y, Hoshikawa M, Tanaka M, Nakatsuka T, Fujiwara H, Miyabayashi K, Takahashi R, Tanaka Y et al (2016) Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. *Oncotarget* 7: 61469–61484
- Zeng L, Zhou M-M (2002) Bromodomain: an acetyl-lysine binding domain. *FEBS Lett* 513: 124–128
- Zeng WF, Navaratne K, Prayson RA, Weil RJ (2007) Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. *J Clin Pathol* 60: 218–221

- Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nussbaum C, Myers RM, Brown M, Li W *et al* (2008) Model-based analysis of ChIP-seq (MACS). *Genome Biol* 9: 1–9
- Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ (2012a) ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. *PLoS ONE* 7: e31127
- Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ (2012b) The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. *Am J Pathol* 181: 1903–1910
- Zhang S, Cui B, Lai H, Liu G, Chia EM, Widhopf GF, Zhang Z, Wu CCN, Chen L, Wu R *et al* (2014) Ovarian cancer stem cells express ROR1, which can be targeted for anti -cancer-stem-cell therapy. *Proc Natl Acad Sci USA* 111: 17266–17271
- Zhang S, Zhang H, Chia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B *et al* (2019) Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. *Proc Natl Acad Sci USA* 116: 1370–1377
- Zhu Q, Liu N, Orkin SH, Yuan GC (2019) CUT and RUNTools: a flexible pipeline for CUT and RUN processing and footprint analysis. *Genome Biol* 20: 1–12